FDA feedback supports planned NDA filingAccording to Gossamer Bio, the FDA indicated that questions surrounding the statistical significance and treatment effect observed in the Phase 3 PROSERA trial would be considered review issues rather than obstacles to accepting the application for filing. Company regains worldwide rights to seralutinibGossamer Bio also announced it has reacquired the worldwide development and commercialization rights to seralutinib from Chiesi after the companies agreed to terminate their collaboration and licensing agreement. The termination ends the previous 50/50 U.S. profit-sharing arrangement and restores international rights to Gossamer Bio without requiring an upfront payment from the company. Under the agreement, Chiesi will make a one-time payment of $5 million to Gossamer Bio. Gossamer Bio stock price